Type 1 Diabetes Market is expected to reach USD 24.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

Q3 2024 Earnings Call Transcript November 6, 2024 Evotec SE misses on earnings expectations. Reported EPS is $-0.12 EPS, ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, acquiring 6.31 million B shares from Novo Holdings for DKK 4.74 ...

The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates. Novo Nordisk ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Novo Nordisk (NVO) has released an update. Novo Nordisk announced that its board members and executives have sold a significant volume of ...

LONDON, Nov 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an ...

Novo Nordisk remains a sell due to increased competition ... These two drugs contributed to Novo's sales, but as can be seen in the above chart they are relatively negligible compared to Ozempic ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations.

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...